Establishment and characterization of a new human erythroleukemic cell line, ERY-1

详细信息    查看全文

• 作者：Ribadeau Dumas ; Antoine ; Hamouda ; Nadine Ben ; Leriche ; Laurence ; Piffaut ; Marie-Claude ; Bonnemye ; Patrick ; et. al.
• 关键词：Human ; CML ; Erythroleukemic ; Cell line ; β ; -Globin ; EPO receptor
• 刊名：Leukemia Research
• 出版年：2004
• 出版时间：December, 2004
• 年：2004
• 卷：28
• 期：12
• 页码：1329-1339
• 全文大小：584 K

文摘

The growth factor-independent erythroleukemic cell line ERY-1 was established from the peripheral blood of a 87-year-old woman with chronic myeloid leukemia (CML) in the acute phase. Immunophenotyping showed that fresh leukemic cells were positive for CD13, CD33, CD36 and CD235a (glycophorin A), a phenotype compatible with that of erythroblastic cells. Cytogenetic and fluorescence in situ hybridization (FISH) analysis demonstrated classical t(9;22)(q34;q11) chromosomic translocation associated with a duplication of the BCR–ABL fusion gene. Other cytogenetic abnormalities were detected in all analyzed mitosis, the most frequent being a trisomy of chromosome 8. The established ERY-1 cell line retains these immunophenotypic and cytogenetic features, and light and electron microscopy confirmed the relatively mature erythroblastic phenotype of the cells. In addition, ERY-1 cell line expressed β-globin mRNA and a non-phosphorylable form of the erythropoietin receptor, even in presence of erythropoietin. Of note, the proliferation of ERY-1 cells was inhibited by TGFβ1 or STI-571 (Gleevec), without significant induction of further differenciation. In conclusion, ERY-1 is a new growth factor-independent human erythroleukemic cell line with a relatively mature phenotype that may be useful to study the molecular events involved in erythroblastic differentiation.